0000899243-18-000454.txt : 20180104
0000899243-18-000454.hdr.sgml : 20180104
20180104160525
ACCESSION NUMBER: 0000899243-18-000454
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180102
FILED AS OF DATE: 20180104
DATE AS OF CHANGE: 20180104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Barrowcliffe Susan E.
CENTRAL INDEX KEY: 0001664251
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 18510105
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD, SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-02
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001664251
Barrowcliffe Susan E.
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
0
1
0
0
General Manager, Europe
Common Stock, $0.0001 par value
2018-01-02
4
M
0
75000
3.022
A
75000
D
Common Stock, $0.0001 par value
2018-01-02
4
S
0
24401
37.1219
D
50599
D
Common Stock, $0.0001 par value
2018-01-02
4
S
0
599
37.7785
D
50000
D
Common Stock, $0.0001 par value
2018-01-02
4
S
0
24700
37.1264
D
25300
D
Common Stock, $0.0001 par value
2018-01-02
4
S
0
300
37.8633
D
25000
D
Common Stock, $0.0001 par value
2018-01-02
4
S
0
24400
37.1195
D
600
D
Common Stock, $0.0001 par value
2018-01-02
4
S
0
600
37.7533
D
0
D
Stock Option (right to buy)
3.022
2018-01-02
4
M
0
75000
0.00
D
2025-05-13
Common Stock
75000
93400
D
The sales reported in the Form 4 were effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $36.58 to $37.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $37.70 to $37.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $36.60 to $37.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $37.85 to $37.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $36.55 to $37.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The transaction was executed in multiple trades in prices ranging from $37.65 to $37.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The option is immediately exercisable in full or in part. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from May 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Susan E. Barrowcliffe
2018-01-04